Apex Biotechnology (TPE:1733) Beginning Cash Position: NT$567 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1733 Apex Biotechnology Corp TPE:1733
81 GF Score
Price NT$30.70
GF Value NT$29.76
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Apex Biotechnology Beginning Cash Position?

Apex Biotechnology TPE:1733 -0.49% 81 Beginning Cash Position is NT$567 Mil as of Mar. 2026. GuruFocus rates TPE:1733 with a GF Score™ of 81/100 and a GF Value™ of NT$29.76 (Fairly Valued). The stock has 3 warning signs investors should review.

Apex Biotechnology's Beginning Cash Position for the quarter that ended in Mar. 2026 was NT$567 Mil.

Apex Biotechnology's quarterly Beginning Cash Position declined from Sep. 2025 (NT$583 Mil) to Dec. 2025 (NT$484 Mil) but then increased from Dec. 2025 (NT$484 Mil) to Mar. 2026 (NT$567 Mil).

Apex Biotechnology's annual Beginning Cash Position increased from Dec. 2023 (NT$332 Mil) to Dec. 2024 (NT$382 Mil) and increased from Dec. 2024 (NT$382 Mil) to Dec. 2025 (NT$533 Mil).

Apex Biotechnology Beginning Cash Position Related Terms

Apex Biotechnology Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Apex Biotechnology's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apex Biotechnology Beginning Cash Position Chart

Apex Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 786.95 555.33 331.71 382.05 532.69

Apex Biotechnology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 532.69 526.62 583.50 484.48 567.09
TPE:1733
81GF Score
Apex Biotechnology Corp TPE:1733
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apex Biotechnology Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of NT$567 Mil mean?
Apex Biotechnology (TPE:1733) has a Beginning Cash Position of NT$567 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Apex Biotechnology and its competitors.
Is Apex Biotechnology's Beginning Cash Position too high?
Apex Biotechnology's current Beginning Cash Position is NT$567 Mil. Overall, Apex Biotechnology has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Apex Biotechnology's Beginning Cash Position compare to VRTX and REGN?
Apex Biotechnology's Beginning Cash Position of NT$567 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Apex Biotechnology and its competitors. Apex Biotechnology's current Beginning Cash Position is NT$567 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apex Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Apex Biotechnology (TPE:1733) is currently considered Fairly Valued. The stock's GF Value™ is NT$29.76, compared to a current price of NT$30.70 — trading 3.2% above its estimated fair value. The current Beginning Cash Position is NT$567 Mil. Apex Biotechnology's overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Apex Biotechnology (TPE:1733), the current Beginning Cash Position is NT$567 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Apex Biotechnology (TPE:1733) Overvalued in 2026?

Based on GuruFocus' analysis, Apex Biotechnology stock appears to be overvalued. The current stock price of NT$30.70 is trading 3.2% above its estimated GF Value™ of NT$29.76. GuruFocus considers Apex Biotechnology to be Fairly Valued.

Key valuation signals for TPE:1733:

  • Beginning Cash Position: NT$567 Mil
  • GF Value™: NT$29.76 vs. price of NT$30.70 (3.2% above fair value)
  • GF Score™: 81/100 with 3 warning signs

No single metric tells the full story. See the TPE:1733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Apex Biotechnology Business Description

Address Li-Hsin 5th Road, No. 7, Hsinchu Science Park, Hsinchu, TWN, 30078
Apex Biotechnology Corp is engaged in the research, development, production, manufacturing, and sale of biochemical testing instruments and proprietary test strips, as well as the import and export of products and components related to its core business. Its product offerings include diabetes testing kits, blood uric acid monitoring systems, blood lactate monitoring systems, blood haemoglobin monitoring systems, etc. The company generates maximum revenue from the sale of test strips, and the rest from testing meters, electrodes, and other products. Geographically, it derives maximum revenue from the USA, and the rest from Italy, Austria, Taiwan, China, and other markets.
81GF Score

Get the complete analysis for TPE:1733

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$30.70
Price
NT$29.76
GF Value